The Prevent Blindness government affairs team has been notified of a potential opportunity to share your story with lawmakers about the harmful impact of “step therapy.” We understand that, in an effort to pass the Safe Step Act into law, legislators want to hear patient stories that will help compel action on this important bill. [Read More]
Category: Latest News
FDA Approves Updated Vabysmo Label To Extend Treatment For Macular Edema Following Retinal Vein Occlusion (Rvo) Beyond Six Months
Genentech has received FDA approval of Vabysmo® for the treatment of macular edema due to retinal vein occlusion (RVO) beyond six months. RVO affects over a million Americans and often involves long-term intravitreal therapy to address the chronic nature of the disease. “This label update reinforces our commitment to delivering consistent, long-term solutions for patients [Read More]
PRIMA System Improves Sight in Individuals With Geographic Atrophy
A study involving participants with geographic atrophy due to dry AMD, has shown that a photovoltaic subretinal implant, combined with glasses that project near-infrared light to the implant, has led to significant improvement in visual acuity in 32 participants. This so-called PRIMA system represents the first eye prosthesis to restore functional sight in people with [Read More]
Geographic Atrophy: Knowledge, Hope, and Help
Are you living with geographic atrophy or have a family member who has been diagnosed with geographic atrophy? If so, please join Prevent Blindness for this 60-minute community forum on Tuesday, October 28th from 7:00-8:00pm Eastern to: Learn about geographic atrophy - what it is, how it is diagnosed, and how it is managed Understand [Read More]
New Drug Approved for Treatment of Macular Telangiectasia Type 2 (MacTel)
Neurotech Pharmaceuticals, Inc. has announced FDA approval of ENCELTO (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel). ENCELTO is the First and Only FDA-approved first and only treatment for MacTel. MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly impacting patients’ quality of [Read More]